After gaining US FDA approval in September 2023, nuclear medicine company Cyclopharm (ASX: CYC) has made an official entry into…
Radiopharmaceutical company Cyclopharm (ASX: CYC) is set to begin commercial sales of its lung imaging device Technegas in the US,…
There’s been a small bump in the road in Cyclopharm’s (ASX: CYC) plans to secure regulatory approval for Technegas™, their…
Australian medtech company Cyclopharm (ASX: CYC) is set to add the United States to the list of 59 countries which…